Biotech & Health
Williams··2 min read
AstraZeneca Secures $1.5B Licensing Deal for Dizal Pharmaceutical's Lung Cancer Therapy
AstraZeneca has agreed to pay up to $1.5 billion for global rights to Dizal Pharmaceutical's targeted lung cancer drug Sunvozertinib, emphasizing global interest in Chinese oncology assets.
Williams··2 min read